Boryung Pharm - Asset Resilience Ratio
Boryung Pharm (003850) has an Asset Resilience Ratio of 8.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 003850 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how Boryung Pharm's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 003850 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Boryung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Boryung Pharm (003850) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩116.42 Billion | 8.59% |
| Total Liquid Assets | ₩116.42 Billion | 8.59% |
Asset Resilience Insights
- Limited Liquidity: Boryung Pharm maintains only 8.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Boryung Pharm Industry Peers by Asset Resilience Ratio
Compare Boryung Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Boryung Pharm (2009–2024)
The table below shows the annual Asset Resilience Ratio data for Boryung Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.40% | ₩4.67 Billion ≈ $3.17 Million |
₩1.16 Trillion ≈ $788.89 Million |
+0.01pp |
| 2023-12-31 | 0.39% | ₩3.59 Billion ≈ $2.44 Million |
₩915.51 Billion ≈ $620.43 Million |
+0.19pp |
| 2022-12-31 | 0.21% | ₩1.84 Billion ≈ $1.25 Million |
₩892.39 Billion ≈ $604.76 Million |
-5.92pp |
| 2021-12-31 | 6.12% | ₩50.73 Billion ≈ $34.38 Million |
₩828.64 Billion ≈ $561.56 Million |
-3.94pp |
| 2020-12-31 | 10.06% | ₩65.21 Billion ≈ $44.19 Million |
₩647.99 Billion ≈ $439.14 Million |
+10.02pp |
| 2019-12-31 | 0.04% | ₩213.73 Million ≈ $144.85K |
₩507.63 Billion ≈ $344.01 Million |
-0.01pp |
| 2018-12-31 | 0.05% | ₩213.18 Million ≈ $144.47K |
₩450.02 Billion ≈ $304.97 Million |
-0.01pp |
| 2017-12-31 | 0.05% | ₩214.70 Million ≈ $145.50K |
₩402.52 Billion ≈ $272.78 Million |
-0.05pp |
| 2016-12-31 | 0.10% | ₩410.37 Million ≈ $278.10K |
₩397.90 Billion ≈ $269.65 Million |
+0.10pp |
| 2012-12-31 | 0.00% | ₩3.82 Million ≈ $2.59K |
₩273.01 Billion ≈ $185.01 Million |
0.00pp |
| 2011-12-31 | 0.00% | ₩3.76 Million ≈ $2.55K |
₩262.39 Billion ≈ $177.82 Million |
+0.00pp |
| 2010-12-31 | 0.00% | ₩2.29 Million ≈ $1.55K |
₩245.86 Billion ≈ $166.61 Million |
0.00pp |
| 2009-12-31 | 0.00% | ₩2.29 Million ≈ $1.55K |
₩176.79 Billion ≈ $119.80 Million |
-- |
About Boryung Pharm
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, So… Read more